Orchidia Pharmaceutical Industries

Equity : February 2026

BIO has invested USD 8 M in equity in Orchidia Pharmaceutical Industries, the leading Egyptian developer and manufacturer of own branded pharmaceuticals generics specialized in the ophthalmic segment.

Amount

$ 8,100,000.00

Type of investment

Equity

Development impacts

Local economic growth
Private sector consolidation/innovation
Access to basic services & goods

Beneficiary locations

Africa: Egypt

Investment field

Enterprises

Activity

C21.2 Manufacture of pharmaceutical preparations

Organisation

Orchidia Pharmaceutical Industries

Website

https://orchidiapharma.com/fr

Orchidia is an SME which offers high quality medicine and provides access to essential healthcare products, improving the lives of millions of patients in Egypt each year. As one of the largest local players in a nascent African healthcare manufacturing market, it secures critical supply of healthcare products.

BIO will follow the lead of SPE III, a top-tier and hands-on PE investor in Africa, in supporting Orchidia to reinforce its management team and implement a renewed ambitious strategic plan to further grow its activities in Egypt and position itself as a regional leader in ophthalmologic pharmaceuticals. The transaction will enable the Company to further create jobs and stimulate the sector in Egypt, thereby making affordable and quality ophthalmologic products available on the local market and reducing imports.

Development impacts

Local economic growth
Orchidia supports 586 jobs, improves job quality per E&S plan, and trained 1,207 young ophthalmologists in 2024. It plans to create 191 new jobs by 2027. Export revenues are set to grow over the coming years diversifying Egypt's trade balance.
Private sector consolidation/innovation
Orchidia, Egypt’s ophthalmic market leader, offers CE-marked products certified by SGS and meeting EU standards. Known for quality and R&D, it develops branded generics and scalable manufacturing, including an in-house microbiology lab. It partners with top research institutions.
Access to basic services & goods
Orchidia offers 87 health products, including 13 unique items with no local alternatives (~4% of 2024 sales). Ophthalmic drugs/devices make up the majority of sales. Through distributors, Orchidia reaches 42,000 pharmacies. Medical convoys serve rural areas. It leads in tender sales , supplying government hospitals for low-income groups.

The investors and the client agreed on an extensive action plan that covers all areas of Orchidia’s activity, including , policies, labor, health and safety, resource efficiency, as well as risks related to climate and gender.

The company holds several certifications and has developed an environmental and social management system with dedicated procedures for the main risks. This is overseen by the EHS team, and by the HR department.

The Environmental and Social (E&S) classification of the project: B+